Coverage, not demand, is now the binding constraint on GLP-1 growth.
With employers retracting coverage and CMS unable to stand up a permanent model, prescription growth now hinges on payer architecture — manufacturer-lobbied subsidies, bridge programs, and formulary gates — rather than patient appetite.
The same conclusion keeps arriving from across the workspace's research — 2 topics independently instantiate this theme. Filter the evidence by where it came from:
Lilly's own strategic admission mirrors the theme that payer willingness, not patient appetite, now caps GLP-1 prescription growth.
The permanent payer mechanism stalls while only the subsidized stopgap extends — coverage architecture, not demand, sets the pace of GLP-1 scaling.
Employer retraction — not patient demand — is now the binding constraint on GLP-1 growth.